256376-24-6 Usage
Uses
Used in Pharmaceutical Industry:
BAY 41-2272 is used as a soluble guanylate cyclase agonist for activating human mononuclear phagocytes and inhibiting vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.
Used in Cardiovascular Applications:
BAY 41-2272 is used as a therapeutic agent for treating various cardiovascular conditions in animal models. It is effective in reducing mean arterial blood pressure in hypertensive rats and has shown to inhibit platelet aggregation and induce relaxation of phenylephrine-preconstricted rabbit aorta rings.
Used in Research and Development:
BAY 41-2272 is used as a research tool for studying the role of soluble guanylate cyclase in various biological processes and its potential as a therapeutic target for cardiovascular diseases.
Biochem/physiol Actions
Cell permeable: yes
Check Digit Verification of cas no
The CAS Registry Mumber 256376-24-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,3,7 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 256376-24:
(8*2)+(7*5)+(6*6)+(5*3)+(4*7)+(3*6)+(2*2)+(1*4)=156
156 % 10 = 6
So 256376-24-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)
256376-24-6Relevant academic research and scientific papers
Straub, Alexander,Stasch, Johannes-Peter,Alonso-Alija, Cristina,Benet-Buchholz, Jordi,Ducke, Bernhard,Feurer, Achim,Fürstner, Chantal
, p. 781 - 784 (2001)
SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described. Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.
Substituted pyrazole derivatives
-
Page column 37, (2010/02/09)
The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
